Abiopharma

🔍 Tolivar Tricia K. (Executive)

Company: CAVA GROUP, INC. (CAVA)

Report Date: 2026-06-15

Detailed Transactions and Holdings:

• Sold 4,969 shares of Common Stock at $89.43 per share (Direct)
  Date: 2026-06-15 | Code: S | equity_swap_involved: 0 | shares_owned_after: 234,931.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3
• Acquired 283 shares of Common Stock at $44.13 per share (Direct)
  Date: 2026-06-15 | Code: A | equity_swap_involved: 0 | shares_owned_after: 235,214.00 | transaction_form_type: 5 | Footnotes: F4, F5, F3
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-06-15 | Code: H | nature_of_ownership: By Spouse | shares_owned_after: 2,500.00

Footnotes:

• F1: The sales reported on this Form 4 represent shares of Common Stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
• F2: The price reported in column 4 represents the weighted average price of 69,803 shares of Common Stock sold by the broker on behalf of employees of the Issuer as a result of mandatory sell to cover transactions associated with the vesting of RSUs. These shares were sold in multiple transactions at prices ranging from $89.00 to $89.87, inclusive. The proceeds of all such sales were allocated to the employees, including the Reporting Person, on a pro rata basis. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
• F3: Includes unvested RSUs.
• F4: Shares purchased pursuant to the CAVA Group, Inc. 2023 Employee Stock Purchase Plan ("ESPP") in transactions that were exempt under Rule 16b-3, for the ESPP purchase period of December 15, 2025 through June 14, 2026.
• F5: In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on December 15, 2025.
• REMARKS: The reporting person states that this filing shall not be an admission that the reporting person is the beneficial owner of any of the securities reported herein as indirectly owned, and the reporting person disclaims beneficial ownership of such securities except to the extent of the reporting person's pecuniary interest therein.